Phathom Pharmaceuticals, Inc. - Common Stock — États financiers (NASDAQ:PHAT) | MetaTrader

Afficher le graphique complet Full chart

Nouvelles

Phathom Pharmaceuticals dépasse les attentes de BPA au T1 2026

Phathom T1 2026 : chiffre d’affaires doublé, rentabilité en vue

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates

Rocket Pharmaceuticals et Argan bondissent en préouverture ; Two Harbors recule légèrement

Barclays relève la note de Phathom Pharmaceuticals sur les perspectives de revenus

Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study

ImmunityBio Rises on China Nod to Bladder Cancer Combo Therapy

Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why

Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli

COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM

Phathom Pharmaceuticals, Inc. (PHAT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug